Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.96 USD
Change Today -0.0099 / -1.02%
Volume 55.1K
DCTH On Other Exchanges
Symbol
Exchange
DCTH is not on other exchanges.
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

delcath systems inc (DCTH) Snapshot

Open
$0.97
Previous Close
$0.97
Day High
$0.99
Day Low
$0.96
52 Week High
04/2/14 - $4.96
52 Week Low
03/30/15 - $0.92
Market Cap
11.7M
Average Volume 10 Days
95.0K
EPS TTM
$-1.63
Shares Outstanding
12.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DELCATH SYSTEMS INC (DCTH)

delcath systems inc (DCTH) Related Businessweek News

No Related Businessweek News Found

delcath systems inc (DCTH) Details

Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe. Its primary focus is on the execution of its clinical development program in ocular melanoma liver metastases, intrahepatic cholangiocarncinoma, hepatocellular carcinoma, and certain other cancers that are metastatic to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.

25 Employees
Last Reported Date: 03/11/15
Founded in 1988

delcath systems inc (DCTH) Top Compensated Officers

Interim Chief Executive Officer, Interim Pres...
Total Annual Compensation: $309.6K
Principal Accounting Officer, Vice President ...
Total Annual Compensation: $199.2K
Executive Vice President of Regulatory Affair...
Total Annual Compensation: $245.6K
Consultant
Total Annual Compensation: $333.6K
Compensation as of Fiscal Year 2013.

delcath systems inc (DCTH) Key Developments

Delcath Systems, Inc. Announces Auditor Changes

On March 12, 2015, Delcath Systems, Inc. dismissed Ernst & Young LLP as its independent registered public accounting firm. On March 13, 2015, the company engaged Grant Thornton, LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2015. The company's stockholders will be asked to ratify this engagement at the company's 2015 annual meeting of stockholders.

Delcath Systems, Inc. Announces Cessation of Peter J. Graham, Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources

Peter J. Graham, Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources of Delcath Systems, Inc., ceased to be employed by the Company effective March 9, 2015. The company has determined to eliminate its in-house legal functions to increase flexibility and cost efficiencies and to focus resources on the clinical development programs of the company.

Delcath Systems, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Delcath Systems, Inc. reported consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenue of $0.3 million was comparable to total revenue of $0.3 million in the fourth quarter of 2013.  Net loss was $2.9 million or $0.31 per diluted share, a decrease of approximately 40%, compared with a net loss of $4.8 million or $0.63 per diluted share a year ago. Operating loss was $3.285 million against $5.526 million a year ago. For the year, the company reported total revenue of $1.1 million compared with $0.8 million in 2013, of which $0.3 million related to the recognition of previously deferred revenue.  Operating loss was $19.3 million, compared with $33.0 million in 2013. Net loss was $17.4 million or $1.84 per diluted share, a decrease of $12.9 million, or 43%, compared with a net loss in 2013 of $30.3 million or $4.81 per diluted share. The narrowing of the net loss is primarily due to a $13.3 million decrease in operating expenses in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DCTH:US $0.96 USD -0.0099

DCTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $17.79 USD +0.05
CTI BioPharma Corp $1.81 USD -0.06
Curis Inc $2.40 USD -0.10
Exact Sciences Corp $22.02 USD -1.01
Sirtex Medical Ltd A$20.74 AUD -0.06
View Industry Companies
 

Industry Analysis

DCTH

Industry Average

Valuation DCTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELCATH SYSTEMS INC, please visit www.delcath.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.